Microbot Medical Inc. Reports $105,000 Revenue in Q1 2026, Net Loss Increases to $3.67 Million

Microbot Medical Inc. reported its financial results for the first quarter of 2026, revealing a revenue of $105,000, a significant increase from zero revenue in the same period of 2025. This revenue was generated from the Limited Market Release of the LIBERTY® Endovascular Robotic System, which the company launched in late 2025. Despite this revenue, the company incurred a net loss of $3.67 million for the quarter, compared to a net loss of $2.6 million in the prior year, reflecting an increase in operational costs associated with ramping up manufacturing and commercialization efforts.

The company's total assets as of March 31, 2026, were approximately $78.07 million, a decrease from $81.54 million at the end of 2025. Current assets included cash and cash equivalents of $3.66 million and marketable securities valued at $68.84 million. The decrease in total assets was primarily attributed to a reduction in cash and marketable securities, as well as an increase in inventory, which rose to $2.26 million from $584,000 at the end of 2025. The company’s total liabilities remained relatively stable at $3.96 million, with current liabilities slightly decreasing to $3.39 million.

Operationally, Microbot Medical has focused on expanding its product offerings and market presence. The company has been actively engaged in the commercialization of its LIBERTY® Endovascular Robotic System, which is designed for minimally invasive surgical procedures. The system's unique features, including its fully disposable design and remote operation capabilities, aim to enhance surgical outcomes while reducing the need for extensive capital equipment. The company has also entered into collaborations, such as with Emory University, to explore the integration of its robotic system with imaging technologies for autonomous procedures.

Looking ahead, Microbot Medical anticipates continued losses as it invests in manufacturing and marketing efforts for the LIBERTY® system. The company has indicated that it will seek additional funding through equity and debt offerings to support its growth initiatives. As of the end of the reporting period, Microbot had approximately $72.5 million in cash equivalents and marketable securities, which management believes will be sufficient to fund operations for more than twelve months. However, the company acknowledges the potential impact of ongoing geopolitical tensions in the region, which could affect its operations and market perception.